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Summary 
Autoantibodies specific against fibrillarin, a 34-kD nucleolar protein associated with U3-snRNP, 
are present in patients with  systemic sclerosis (SSc).  To understand the mechanisms involved 
in the induction of these autoantibodies, we prepared a series of human fibrillarin recombinant 
proteins covering the entire molecule and analyzed their interaction with the autoantibodies present 
in various connective tissue diseases.  Our results showed that antifibrillarin autoantibodies are 
present not only in SSc, as previously reported, but also in a variety of other connective tissue 
diseases.  Patients with SSc (58%),  mixed connective tissue diseases  (60%),  CREST syndrome 
(calcinosis, Raynaud phenomenon, esophageal dismotility, sclerodactyly, and telangiectasia syn- 
drome) (58%), systemic lupus erythematosus (39%), rheumatoid arthritis (60%), and Sjogern's 
syndrome (84%) showed presence of antifibrillarin autoantibodies. Results obtained from com- 
petitive inhibition radioimmunoassay and Western blot analyses with purified recombinant fu- 
sion proteins revealed that these autoantibodies react primarily with epitope(s) present in the 
NH2-  (AA  1-80)  and COOH-terminal  (AA 276-321)  domains of fibriUarin.  Autoantibodies 
reacting with internal regions of fibrillarin are less frequent. Analysis of the hydrophilicity profiles 
of reactive peptides showed presence of three potential antigenic sites in the NH2- and two in 
the COOH-terminal regions. While a hexapeptide sequence NH2 terminus of fibrillarin is shared 
with an Epstein-Barr virus-encoded nuclear antigen, the COOH-terminal region shares sequence 
homology with P40, the capsid protein encoded by herpes virus type 1. Interestingly, these two 
regions of fibrillarin also contain the most immunodominant sequences, as predicted by surface 
probability and the Jameson and Wolf antigenic index. These observations suggest that molec- 
ular mimicry might play an important role in the induction of antifibrillarin autoantibodies. 
p resence of antinuclear antibodies is a hallmark of rheu- 
matic autoimmune diseases (1). Autoantibodies reacting 
with nuclear proteins like Smith antigen, (Sm) 1, topoisomer- 
ase I, centromere proteins, and amino-acyl tRNA synthetase 
are characteristic for SLE (2),  systemic sclerosis (SSc) (3), 
CREST syndrome (calcinosis, Raynaud phenomenon, esopha- 
geal dysmotility, sclerodactyly, and telangiectasia syndrome) 
(4),  and polymyositis (5),  respectively. Although pathoge- 
nicity of these antibodies has not been established, they are 
useful as markers in the differential diagnosis. In addition to 
the antinuclear autoantibodies, antibodies reacting with specific 
nucleolar proteins have been reported in systemic autoimmune 
diseases (6). For instance, RNA polymerase I (7), 7-2RNP 
1  Abbreviations used in this  paper: CREST, calcinosis,  Raynaud  phenomenon, 
esophageal dismotility, sclerodactyly,  and telangiectasia  syndrome; GST, 
glutathione-S-transferase;  ItrIG, isopropyl-/~-D-thiogalactopyronoside;  MBP, 
myelin  basic protein; MCTD, mixed connective  tissue diseases; MS, mul- 
tiple sclerosis;  RA, rheumatoid  arthritis; Sm, Smith antigen; SS, Sjogern's 
syndrome; SSc, systemic sclerosis. 
(8), PM-Scl (9) and U3 snRNP-associated fibrillarin (10, 11) 
are targets of scleroderma autoantibodies. Antifibrillarin anti- 
bodies may characterize a subset of patients with diffuse scle- 
rosis and widespread telangiectasia (12). In contrast to humans, 
production of autoantibodies specific for nucleolar antigens 
is seldom associated with the spontaneous development of 
systemic autoimmune diseases in animals. However, antifibril- 
larin antibodies can be induced in B10.S and SJL mice after 
injection with mercuric chloride (13,  14). 
Fibrillarin is a highly conserved 34-kD nucleolar protein 
localized in the fibrillar regions of nudeoli (10,  11). It is as- 
sociated with U3 snRNP complex, which is thought to play 
a role in the processing of preribosomal RNA (15).  Fibril- 
larin has three distinct domains: (a)  NH2-terminal domain 
of 80 amino acids rich in glycine and dimethylarginine; (b) 
central domai~a of 90 amino acids containing the RNA binding 
consensus octomeric sequence; and (c) COOH-terminal  a 
helical domain of 151 amino acids (16).  The genes coding 
for fibrillarin of Xenopus  laevis  (17),  Physarum polycephalum 
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cloned and sequenced.  The primary structure of fibrillarin 
from these sources shows a high degree of  homology to human 
fibrillarin. 
Antifibrillarin antibodies are currently demonstrable either 
by immunofluorescence or immunoprecipitation  methods. Use 
of these  techniques  has  shown  that  a  small  fraction  of 
scleroderma  sera-3.4%  (22),  6%  (23),  and 3.6%  (24)- 
contain antifibrillarin autoantibodies. The major drawback 
of these methods is their inability to discern the specificity 
of the antibodies reacting with large macromolecular com- 
plexes that were used in such analysis. The nucleolar extracts 
enriched for U3 RNP complex that were used in immuno- 
precipitation analyses also contain five other polypeptides with 
molecular masses of 74, 59, 30, 13, and 12.5 kD, in addition 
to fibrillarin (25). Presence of autoantibodies against any one 
of the polypeptides associated with fibrillarin can also bring 
down fibriUarin by immunoprecipitation via the sera that may 
contain these antibodies. Furthermore, fibrillarin is also found 
associated with other less abundant snRNPs such as US, U13, 
U14,  X, and Y (26). In a recent report, out of seven mAbs 
obtained from mercuric chloride treated A.SW mice that 
precipitated  U3 RNP and showed positive nucleolar staining 
of Hep2 cells by immunofluorescence, only four mAbs im- 
munoprecipitated purified human fibrillarin (27). 
Therefore, we have developed a reliable and sensitive solid- 
phase RIA, using purified human recombinant fibrillarin pro- 
teins, first to study the frequency of antifibrillarin autoanti- 
bodies present in scleroderma patients and then to determine 
whether they are present in other connective tissue diseases. 
Our results demonstrate that antifibrillarin antibodies are 
present in high frequency not only in SSc but also in a va- 
riety of other connective tissue such as diseases like mixed 
connective tissue disease (MCTD), SLE, CREST syndrome, 
rheumatoid arthritis (RA), and Sjogern's syndrome (SS). By 
preparing a panel of six overlapping fibrillarin  fusion pro- 
teins, we have also determined whether these autoantibodies 
are directed against a common epitope(s)  or a characteristic 
set of epitopes  in each disease. Our results showed that the 
autoantibodies from various connective tissue diseases exhibited 
a similar immunochemical specificity suggesting that the same 
or similar epitopes  are recognized. However, in contrast to 
autoantibodies present in SSc, MCTD, SLE, and CREST syn- 
drome, which reacted primarily with the epitopes located at 
the NH2-terminal region, autoantibodies present in RA and 
SS  reacted  equally well  with  the  epitopes  present  at  the 
NH2- and COOH-terminal regions. 
Materials  and Methods. 
Sera.  Sera  were obtained from patients with various connec- 
tive tissue diseases such as SSc, CREST syndrome, MCTD, RA, 
SS, and SLE and control healthy subjects were stored at  -20~ 
until use (the patients were classified  by the criteria described by 
the American Association of Rheumatism). A total of 237 serum 
samples (56 SSc, 81 SLE, 22 MCTD,  11 CREST  syndrome, 38 
RA, 15 SS, and 14 heahhy subjects) were used in this study. 
Antigens.  Recombinant human fibrillarin fusion proteins, hu- 
man Sm antigen (kindly provided by Dr. H. Dang, University of 
Texas, San Antonio, TX), rat collagen I (from Dr. R. Holmdahl, 
University  of Uppsala, Uppsala, Sweden), human myelin  basic pro- 
tein (MBP) (from G. Hashin, Saint Lukes Hospital, New York), 
and dsDNA were used as antigens in the direct-binding and com- 
petitive inhibition RIA. Recombinant fusion proteins containing 
five contiguous moieties of human fibrillarin were obtained by 
cloning the corresponding cDNA sequences into pGEX-2T ~ ex- 
pression vector (28). 
Expression Cloning of Human Fibrillarin cDNA.  The coding re- 
gion of  human fihrillarin cDNA (cDNA clone kindly provided by 
Dr. J. Aris, University of Florida, GainseviUe, FL) and the DNA 
sequences corresponding to amino acid residues 1-321, 1-85, 86- 
148, 149-229, 230-275, and 276-321 of fibrillarin were amplified 
with oligonucleotide primers by PCR (29). The amplified DNA 
fragments were subcloned into pGEX-2T expression vector, which 
expresses glutathione-S-transferase  (GST). The cloned  cDNAs were 
expressed as GST fusion proteins. Schematic representation of the 
fibrillarin regions that were cloned is shown in Fig. 1. The fol- 
lowing primers were used for PCR amplification: (a) primer 01: 
5'-atgaagccaggattcagtccc-3';  primer 321: 5'-gttcttcaccttggggggtgg- 
3'; (b) primer 01: 5'-atgaagccaggattcagtccc-3'; primer 85: 5'-aat- 
gtgatggtggagccgcat-3'; (c) primer 86: 5'-attcttccccgactggtttcc-3'; 
primer 148: 5'-gattgctgctgctagcttggag-3';  (d) primer 149: 5'-atc- 
ctgggtggtgtggacca-3'; primer 229: 5'-cattgcgatgagcatgcggta-3';  (e) 
primer 230: 5'-atgctggatctgatctttgctg-3';  primer 275: 5'-ggctga- 
ggctgtggagtcaa-Y; and (f) primer 276: 5'-gaggccgtgtttgcctccga- 
Y; primer 321: 5'-gttcttcaccttggggggtgg-3'.  The 5' and 3' end 
primers contained BamHI and EcoRI sites, respectively, at the 5' 
end of the sequence. The amplified  DNAs were digested with re- 
striction enzymes,  ligated  to BamHI-EcoRI-cut pGEX-2T plasmid, 
and the Bb21 competent cells were transformed. The bacteria ex- 
pressing the recombinant  phsmids were selected  on ampiciUin  plates. 
The recombinants were grown in I ml Lubria broth (LB) medium 
and induced  with 1 mM isopropyl  B-D-thiogalactopyronoside  (IFIG) 
for 5 h at 37~  The bacterial lysates  were run on SDS-polyacryl- 
amide gels, and the recombinants expressing appropriate molec- 
ular size fusion proteins were selected. Plasmid DNAs  were se- 
quenced by the dideoxy chain termination method (30), with an 
oligonucleotide  primer 5'-gcatggcctttgcaggg-3', corresponding to 
855-871 of the pGEX sequence, to confirm that the inserts were 
cloned in frame. 
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Schematic diagram showing regions of 
human fibrillarin  cloned as fusion proteins 
Figure 1.  Schematic  diagram showing  regions of human fibrillarin  ex- 
pressed as fusion  proteins. DNA fragments  coding  for defined  regions of 
fibrillarin  A-F generated  by PCR were cloned into pGEX-2T expression 
vector to produce six in-frame  fusion proteins as described in Materials 
and Methods. FibriUarin  proteins containing  13 hydrophilic  regions were 
kept intact to preserve the potential  antigenic  sites formed  by linear  amino 
acid sequences. 
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were coated with recombinant fusion proteins or GST (as control) 
at 5 #g/ml in carbonate buffer, pH 9.0, at 4~  overnight. After 
washing, the plates were blocked with 3% BSA in PBS for 1 h 
at room temperature, washed  three times, and incubated with 1:400 
dilution of sera for 2 h. After thorough washing, 5  x  104 cpm 
of 12SI-labeled rabbit F(ab')2 anti-human  y antibody in 50 #1 was 
added and incubated for a further 2 h. After washing, the bound 
radioactivity was measured in a gamma counter. Cpm bound to 
GST coated plates were subtracted from the cpm bound to fibril- 
latin fusion protein-coated plates and expressed as specific cpm 
bound. 
Competitive Inhibition Assay.  10/~g/ml of serum IgG, purified 
by use of protein A-Sepharose or  1 #g/ml of affinity-purified 
antifibrillarin antibodies, was incubated with various amounts of 
collagen I, Sin, dsDNA,  MBP, or fibrillarin in 50 #1 for 1 h at 
room temperature, and then transferred to fibrillarin-coated  plates 
following the procedure described previously  (31). The cpm bound 
to fibrillarin was measured as above. The inhibition was expressed 
as a percentage. 
Western Blotting.  Purified  fibrillarin fusion proteins were run 
on 10% polyacrylamide  gels in the presence of  SDS (32). Separated 
proteins were transferred to nitrocellulose filters (33) at 100 V for 
4 h at 4~  blocked with 5% BSA in PBS, and then incubated 
for 1.5 h with a 1:500 dilution of  human sera or 0.1 #g/ml of  mouse 
anti-human fibrillarin  mAb in PBS containing 5% BSA and 0.05% 
Tween 20. After washing with PBS containing Tween 20, filters 
were incubated for  1.5 h  at room temperature with 125I-rabbit 
P(ab')2 anti-human Igy or ml-labeled rat anti-mouse &K mAbs 
at 2  ￿  105 cpm/ml.  Filters were washed, dried, and autoradio- 
graphed as previously described (31). 
Indirect Immunofluorescence.  NIH 3T3 cells  were grown on glass 
coverslips in 35-mm dishes. After 2 d in culture at 60% confluence, 
the cells were washed with PBS and then fixed with 2% parafor- 
maldehyde in PBS, pH 7.4, for 15 rain at room temperature. The 
fixed cells were permeabilized by exposure to 0.2% Triton X-100 
in PBS for 5 rain on ice. After permeabilization, cells were rinsed 
three times for 10 rain with PBS and incubated with 50/zg/ml 
of IgG antibodies or 5 #g/ml of affinity-purified  antibodies diluted 
in 1% goat serum for 1 h at room temperature. The unbound anti- 
body was removed by rinsing three times for 10 rain with PBS 
and then incubated with affinity-purified  goat F(ab')z anti-human 
IgG antibody conjugated with FITC at a dilution of 20 #g/ml 
for 1 h. The unbound second antibody was removed by washing 
with PBS, and the cells were mounted in 90% glycerol, 10% PBS 
(pH 8.0) containing 4% n-propyl gallate (34). The cells were ex- 
amined under fluorescence  illumination or laser light in a micro- 
scope (Carl Zeiss, Inc., Thornwood,  NY). 
Results 
Expression and Purification of Recombinant Fibrillarin Pro- 
teins.  To identify the immunodominant B cell epitopes of 
fibrillarin, the PCK-amplified DNA fragments coding for 
various moieties of fibrillarin (Fig.  1), each containing one 
to three hydrophilic regions, were cloned into pGEX-2T ex- 
pression plasmid, Thus, a panel of six in-frame contiguous 
fibrillatin fusion proteins  were  generated  as  described  in 
Materials and Methods. Bacterial cultures expressing recom- 
binant proteins were induced with IPTG, and the fusion pro- 
teins were purified by affinity chromatography on a gluta- 
thione-S-Sepharose  gel column as previously described (28). 
Total bacterial lysates and purified recombinant proteins run 
on SDS-PAGE and stained with Coomassie blue R  stain are 
shown in Fig. 2. The level of induction of recombinant fu- 
sion proteins varied depending on the insert sequence.  The 
expected molecular mass of fibrillarin fusion proteins FP-A, 
FP-B, FP-C, FP-D,  FP-E,  and FP-F were 60.0,  34.5,  32.5, 
34.1, 30.6,  and 30.6 kD, respectively. The observed  sizes of 
fusion proteins correspond well to this (Fig. 2). All recom- 
binant proteins were full-length products. Only FP-C fusion 
protein showed lower molecular mass derivatives, indicating 
proteolytic cleavage in specific regions of fibrillarin. Sequence 
analysis of recombinant plasmid DNAs confirmed that the 
insert DNAs were inframe with the gent coding for GST 
protein. 
Frequency of  Antifibrillarin Antibodies in Sera of Patients with 
Connective Tissue Diseases.  The presence of antifibrillarin an- 
tibodies in the sera of individuals with various connective 
tissue diseases was studied by solid-phase RIA with purified 
fibrillarin fusion protein FP-A. Background binding to GST 
was determined by parallel assays on GST-coated plates. Cpm 
bound to GST protein was subtracted from total cpm bound 
to fibriUarin fusion protein. The specific binding activities 
of sera from patients with various connective tissue diseases 
are presented as cpm bound in a scatter diagram (Fig.  3). 
The sera showing three- to fourfold higher binding than that 
of the control healthy subjects were considered positive.  To 
confirm the results obtained by RIA and exclude any false 
positives, we tested all available positive sera on Western blots 
containing purified fibrillarin fusion protein and GST. The 
sera were preabsorbed with GST-coupled Sepharose 4B to re- 
move the antibodies that might react with GST. We also in- 
cluded a mouse antifibrillarin mAb and four sera from healthy 
humans as positive and negative controls, respectively. Rep- 
resentative Western blots are shown in Fig. 4.  The results 
showed a strong positive correlation between ILIA and Western 
blot assay methods. The high sensitivity of the immunoblot 
analysis method is clearly demonstrated by the strong fibril- 
latin band signal in the blot incubated with mouse antifibril- 
latin mAb at 0.1  /zg/ml. 
The data summarized in the histogram (Fig. 5) show that 
'~58%  of SSc patients have significant titers of antibodies 
that bind to fibrillarin fusion proteins. A similar percentage 
of patients with CREST syndrome (58%), MCTD (60%), 
RA (59%),  and SLE (39%) also exhibited the presence  of 
these antibodies. To our surprise,  >84% of patients with St 
showed high titers of antifibriUarin antibodies. Thus, our data 
clearly show that antifibrillarin autoantibodies are present at 
high frequency not only in patients with SSc but also a va- 
riety of other connective tissue diseases. 
Epitope Specificity  of  Antifibrillarin Antibodies.  KIA was per- 
formed by use of fibrillarin fusion proteins FP-B, FP-C, FP-D, 
FP-E, and FP-F to determine the domains of fibrillarin that 
interacted with the autoantibodies. The sera exhibiting sig- 
nificant titers of antifibrillarin antibodies were further tested 
by direct binding assay with purified fibriUarin fusion pro- 
teins FP-B to FP-E Out of 56 SSc sera, 31 showed significant 
binding to fibrillarin fusion protein FP-A, 30 to FP-B, 5 to 
1029  Katsuri  et al. Figure  2.  Analysis  of recombinant fibril- 
latin  fusion  proteins.  Coomassie  blue- 
stained polyacrylamide gels show lysates of 
bacteria expressing fusion proteins A-F (A) 
and the purified  fusion proteins  (B).  Fu- 
sion proteins were purified by affinity chro- 
matography on glutathione~S-Sepharose  gel 
as described in Materials and Methods. The 
observed molecular sizes of  fusion proteins 
A-F correspond well to the predicted mo- 
lecular  masses of 60.0,  34.5,  32.5,  34.1, 
30.6,  and 30.6  kD,  respectively. 
FP-D, and 8 to FP-F (Table 1). Only 1 sample failed to bind 
to any fusion protein other than the complete fibrillarin mol- 
ecule. The titer of antibodies against individual epitopes  present 
in this sera may be low and is not quite sufficient to show 
above the background when individual fusion proteins were 
used, or it is a conformational site that was lost as individ- 
ual fusion proteins were prepared. Sera from MCTD, SLE, 
CREST, ILA, and SS showed high frequency of binding ac- 
tivity to the fusion protein, FP-B, containing  the NH2-ter- 
minal region. Comparison of binding profiles of sera from 
SSc, MCTD, SLE, and CILEST disease groups revealed no 
specific patterns of antibody reactivity. The frequency of an- 
tibody reacting with the immunodominant epitope present 
on FP-B and FP-F did not show significant difference  between 
the above disease groups.  However, sera from RA and SS 
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Figure 3.  Binding activity of sera from various connective tissue dis- 
eases to fibrillarin.  The binding activity was measured by RIA with sera 
at 1:400 dilution as described in Materials and Methods.  Optimum dilu- 
tion of the serum to use in the assays was determined by preliminary assays. 
Cpm bound to GST was subtracted  from the cpm bound to fibrillarin 
fusion protein. The mean values of triplicate assays are shown in the scatter 
diagram.  Each dot represents  an individual  serum. 
showed a high frequency of  binding to the COOH-terminal 
portion corresponding to amino acid  residues 276-321 (FP-F). 
This is comparable to the binding activity to the immuno- 
dominant epitope present on FP-B. This suggests that anti- 
FP-F antibody may be an additional marker to discriminate 
ILA and SS from other connective  tissue disorders. The binding 
specificity  and the pattern of reactivity of autoantibodies were 
confirmed  by Western blot analysis. Samples of positive sera, 
selected randomly, were tested at 1:500 dilution on Western 
blots. The binding profiles of several sera were examined in 
Western blots containing fusion proteins FP-A to FP-F. Rep- 
resentative Western blots are shown in Fig. 6. Distinct pat- 
terns of  binding by different sera demonstrate that a number 
of  epitopes are recognized by the autoantibodies, confirming 
the results obtained by direct-binding  ILIA. This assay also 
shows that the antibodies demonstrated are specific and do 
not react with GST. The amount of antibodies bound to the 
fusion protein FP-B band in Western blots appears to be some- 
what lower than that detectable in ILIA (data not shown). 
This may be due to reduced availability of some conforma- 
tional  epitopes present  on FP-B after SDS denaturation. 
Specificity of  Antifibrillarin Antibodies.  To determine whether 
the autoantibodies present in these disease groups are specific 
to fibrillarin, we tested the binding activity of autoantibodies 
by competitive inhibition ILIA by use of several  autoantigens 
as competitive inhibitors (collagen I, Sin, dsDNA, and MBP 
are target autoantigens  in SSc, SLE, and multiple sclerosis 
[MS]). Results of  inhibition ILIA of  four antibodies are shown 
in Fig. 7. The specificity of affinity-purified antibodies ob- 
tained from a SSc serum that was also used in Western blot 
analysis is shown in Fig. 7 A. Preincubation of purified anti- 
bodies with chromatographically purified soluble recombinant 
fibrillarin inhibited the binding of autoantibodies to fibrillarin- 
coated plates, while other autoantigens used as inhibitors did 
not show any significant  inhibition. Results of  inhibition assays 
1030  Fibrillarin  Epitopes  Recognized by Autoantibodies Fig,,re  4.  Demonstration  of the presence  of antifibrillarin autoantibodies in connective  tissue diseases. Purified  recombinant human fibrillarin  and 
GST were separated on 10% SDS-PAGE,  blotted to nitrocellulose,  and reacted with sera as described  in Materials and Methods. Human sera were 
used at 1:500  dilution. Mouse  anti-human  fibrillarin  mAb (0.10/~g/ml)  and sera  from  heathy  human subjects were  used  as positive  and negative  controls. 
Representative autoradiograms of Western blots reacted with control sera, SSc (PSS), MCTD, SLE, CREST, RA, and SS are shown. 
of sera from SSc, MCTD,  and SLE shown in Fig.  7, B-D, 
further demonstrate that the autoantibodies detected by RIA 
are specific to fibriUarin and are devoid ofpolyreactivity. Similar 
results were obtained with sera from patients with RA and 
SS (data not shown). 
Indirect  Immunofluorescence  Analysis.  Total serum IgG from 
SSc patients,  and affinity-purified antifibrillarin antibodies, 
from the fusion protein FP-A affinity column were used for 
determining the pattern of binding to nuclear components 
on freshly cultured 3T3 cells by immunofluorescence  and con- 
focal microscopy. The number of nucleoli per cell vary de- 
pending on the cell type used. The 3T3 fibroblasts show two 
to several nucleoli (10). IgG from SSc patients showed bright 
nucleolar staining with very weak or no staining of nucleo- 
plasm (Fig.  8, B). On the other hand, affinity-purified anti- 
fibrillarin antibodies,  in addition to brightly staining nucleolar 
material, also stain the nucleoplasm feebly but consistently. 
The weaker staining of nucleoplasm by total IgG may be due 
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Figure  5.  Frequencies  of  patients with antifibrilllarin  antibody  activity 
in connective  tissue  diseases. The numbers of  sera exhibiting  two- to four- 
fold  higher  binding  activity  than the mean value  of  sera from healthy  indi- 
viduals are shown as percentages in the histogram. 
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to the polyclonal nature of the antibodies present. In other 
words,  in  these sera,  antibodies  that  are specific  for other 
nucleolar proteins are probably more abundant than antifibril- 
larin antibodies. Staining of fibrillar regions of the nucleolus 
was more evident when affinity-purified  antibodies were used. 
Corrfocal microscopy confirmed that the staining of the fibriUar 
and  granular  regions  of the  nucleolus is  characteristic  of 
antifibrillarin antibodies  (Fig.  8  G). 
Discussion 
Autoantibodies reacting with nucleolar proteins are pro- 
duced in connective tissue diseases such as SSc, SLE, and SS 
(6). Autoantibodies present in SSc show diverse binding pat- 
terns in immunofluorescence staining, suggesting that a va- 
riety of autoantigens might be recognized. The molecular 
nature of some of these autoantigens has been described re- 
cently. A distinct nucleolar protein, fibrillarin,  associated with 
U3-snRNP, has been reported as a target autoantigen recog- 
nized by autoantibodies present in diffuse scleroderma (10). 
Immunofluorescence staining with antifibrillarin antibodies 
shows staining of fibrillar and granular regions of the nucleoli 
Table 1.  Epitope Specificity of Anti-Fibrillarin Autoantibodies 
Disease  Fibrillarin  FP-B  FP-C  FP-D  FP-E  FP-F 
PSS  31/56  30  0  5  0  8 
MCTD  13/22  10  1  6  0  2 
RA  22/38  14  0  6  0  17 
SS  13/15  8  0  3  0  11 
CREST  6/11  4  0  2  0  4 
SLE  30/80  22  0  5  0  10 Figure  6.  Western blot analysis of autoimmune sera from connective 
tissue diseases. Selected examples of sera reactive with fibrillarin  fusion 
proteins  are shown.  Western  blots containing recombinant  fusion  pro- 
teins A-F were incubated with a 1:500 dilution of autoimmune sera and 
developed with lzsI-labeled  rabbit F(ab')2 antibody  specific for human Ig~ 
chain. (A) SSc serum. (B) MCTD serum. (C) SSc serum. (D) SLE serum. 
(9). The distribution of  fibriUarin staining parallels RNA poly- 
merase I staining (7).  Our results clearly demonstrate that 
affinity-purified antifibrillarin  antibodies stain fibrillar regions 
of the  nucleolus  (Fig.  8).  Since  the  immunofluorescence 
method does not allow precise identifcation of the antigens 
involved,  we used a sensitive  RIA with recombinant fibril- 
larin fusion proteins to define B cell epitopes.  In this paper, 
we present data demonstrating that antifibrillarin antibodies 
are produced not only in SSc, as described previously (12), 
but also in a variety of other rheumatic diseases. Thus, the 
frequency of antifibrillarin antibodies occurring in MCTD, 
CREST syndrome, and RA is comparable to that observed 
in SSc, while these antibodies are more prevalent in SS (84%) 
but less common in SLE patients  (39%). 
There is a striking difference  between our results and those 
previously reported with respect to  the frequency of anti- 
fibrillarin autoantibodies in scleroderma. While the results 
obtained by immunofluorescence and immunoprecipitation 
methods showed an incidence of 3.4-6% (22-24), our results 
obtained by RIA showed a frequency of 58% among sclero- 
derma patients.  Positive  sera  identified by RIA  were also 
confirmed to be positive in Western blot analysis. High corre- 
lation between RIA and Western blot analysis results rules 
out the possibility of high false positives in RIA.  The dis- 
crepancy between our results obtained by RIA  and those 
obtained by immunofluorescence and immunoprecipitation 
methods can be explained by (a) higher sensitivity of ILIA 
compared with immunofluorescence  and immunoprecipitation 
methods, and (b) use of purified recombinant human fibriUarin 
in R.IA in which all epitopes are available for interaction with 
antibodies. Thus, use of RIA and Western blot analysis with 
purified recombinant human fibrillarin allowed the detection 
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Figure  7.  Demonstration  of the 
specificity of antifibriUarin autoan- 
tibodies by competitive inhibition 
ILIA. Various concentrations of an- 
tigen,  1-20  /~g/ml,  were  mixed 
with 1/~g/ml of  affinity purified an- 
tibody or 10 #g/ml of IgG from 
different  sera, preincubated,  and 
then transferred to fibrilhrin-coated 
plates, and the inhibition was cal- 
culated as described in Materials and 
Methods.  (A) Affinity-purified an- 
tibody isolated from an SSc serum. 
(B)  SSc serum  IgG.  (C)  MCTD 
serum  IgG.  (D) SLE serum  IgG. 
1032  Fibrillarin  Epitopes  Recognized by Autoantibodies Figure  8.  Indirect immunofluorescence  staining of 3T3 cells with antifibriUarin antibodies. Freshly grown 3T3 cells were fixed with paraformalde- 
hyde, incubated with SSc serum Ig or affinity-purified  antifibrillarin antibodies, and stained with FITC-labeled  F(ab')2 goat anti-human IgG antibodies. 
Phase (A, C, and E) and immunofluorescence  patterns (B,/9, and F) are shown. (,4 and B) Cells incubated with SSc lgG. (C and D) Cells incubated 
with af~nity-purified antifibriUarin antibodies isolated from a SSc patient. (E and F) Cells incubated with FITC-labeled second antibody alone. (G) 
C~nf~ca~micr~sc~peimage~fthe~bri~arregi~ns~fnuc~e~iince~sstainedwitha~nity~uri~edanti~bri~arinantib~dies.  xlOO(A-EandF);  x250(G). 
of antifibrillarin autoantibodies  in the sera of patients  with 
other connective tissue diseases. It is of  interest that the pres- 
ence of antifibriUarin antibodies has been reported in certain 
malignant diseases such as hepatocellular  carcinoma (35). 
Antifibrillarin  antibodies present in connective tissue dis- 
eases are highly specific to fibrillarin antigen.  Results from 
competitive inhibition  RIA demonstrate that  binding of 
affinity-purified antifibrillarin antibodies and autoantibodies 
present in the sera to fibriUarin antigen-coated plates is in- 
hibited only by soluble fibrillarin and not by other autoan- 
tigens such as DNA, Sin, collagen type III, and MBP, which 
are target antigens in SLE, SSc, and MS. These data, as well 
as low binding to BSA or GST, suggest that antifibrillarin 
autoantibodies are not endowed with polyspecific  properties. 
The variation in the degree of inhibition between different 
sera might be due to differences  in the concentration, affinity, 
and epitope specifcity of antibodies present in different sera. 
The data obtained from RIA and immunoblotting of fibril- 
larin fusion proteins, encompassing the entire fibrillarin poly- 
peptide sequence, show that the immunodominant B cell epi- 
topes are located in the NH2-terminal  glycine-arginine-rich 
region, since most of the SSc sera, as well as sera  from MCTD, 
SLE, and CREST syndrome, react with FP-A, the complete 
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fibrillarin, and the fusion protein FP-B, which contains the 
NH2-terminal  moiety.  About 15-30%  of SSc patients  also 
had antibodies  that bound to the COOH-terminal region 
of  fibrillarin, FP-F, while a small percentage of sera also  bound 
to FP-D, the internal helical region. The autoantibodies that 
bound to the NH2-terminal  portion are distinct from those 
that bind to the epitopes present in the COOH-terminal re- 
gion because all the sera that showed binding to FP-B did 
not bind to FP-F. Western blot analysis  confirmed R.IA results. 
In Western blots, the antibodies present in some sera recog- 
nized only NH2-terminal  fusion protein, while others rec- 
ognized only COOH-terminal peptide (Fig. 6). Antibody 
profiles obtained for RA and SS, by use of recombinant fu- 
sion proteins,  showed higher correlation  of the presence of 
anti-FP-F antibody with the disease. The variation in the epi- 
tope  reactivity  and  specificity of autoantibodies  may be 
influenced by factors such as the duration or severity of the 
disease, HLA haplotype  of the patient,  and nature of the 
therapy. 
Swiss-Protein data base search revealed the presence of ho- 
mology between the NH2-terminal portion of fibrillarin and 
R.NA binding proteins from various sources  and EBV-encoded 
nuclear protein (Fig. 9). The NH2-terminal portion of fibril- 69  80 
Fibrillarin  NRGP~RGGKRGN 
:::::: 
EBV encoded NP  SGGRGRGGSGGR 
334  345 
311  321 
Fibrillarin  GVYRPPPKVEN 
.:::::: 
RSV(type i)  P40  AVYRPPPHSAP 
533  544 
Figure  9.  Comparison of amino acid sequences of fibrillarin  peptide 
motifs sharing homology with foreign antigens.  Hydrophilic fibrillarin 
peptide motifs (potential antigenic sites) exhibiting sequence  similarity 
with a nuclear  protein encoded by EBV genome and capsid protein P40 
encoded by HSV type 1 are shown.  :, amino acid identity;.,  conserved 
changes. 
larin (fusion protein FP-B) contains three hydrophilic regions 
corresponding to aa residues 17-28, 33--48, and 66-84. Based 
on the analysis of surface probability and Jameson and Wolf 
antigenic index of these regions, as predicted by GCG anal- 
ysis (Genetic Computer Group, Madison, WI), the aa res- 
idue sequence 66-84 appears to be the most irnmunodominant 
one in this region. This fusion protein is recognized by a 
majority of autoimmune sera. Interestingly, this region con- 
rains a hexapeptide sequence, GKGKGG, which is shared with 
EBV-encoded nuclear antigen (36). The next most commonly 
recognized fusion protein, FP-F, by autoimmune sera, con- 
tains the COOH-terminal portion of fibrillarin. This region 
contains two hydrophilic regions at aa residues 281-306 and 
314-321.  The first hydrophilic region bears high homology 
with yeast fibrillarin  as well as some self-proteins  such as 
chicken myosin heavy chain and microtubule associated protein 
1A (37). The most antigenic peptide in this region is aa se- 
quence 311-319, GVYtLPPPK (Fig. 9), bearing sequence ho- 
mology with capsid protein P40 encoded by HSV type 1 (38). 
One may ask how antifibriUarin autoantibodies are induced 
in patients with various connective tissue diseases. The first 
possibility is that the peptides that were generated from the 
nucleolar protein fibrillarin,  derived from the endogenous 
pathway, are transported to the surface, where they are rec- 
ognized by fibrillarin-specific lymphocytes. In this mecha- 
nism, it remains unclear why antifibrillarin antibodies are pro- 
duced only in patients with connective tissue  diseases and 
not in healthy subjects or in patients afflicted with other dis- 
eases. Whether MHC or analogous molecules play a role in 
presentation of the peptides derived from fibrillarin remains 
to be determined. The second possibility is that environmental 
factors, chemicals, or drugs might play a role in presentation 
of these self-peptides to T lymphocytes, leading to their am- 
plification,  and thereby help in the activation of autoreactive 
B cells. The presence of elevated levels of antifibrillarin  anti- 
bodies in mercuric chloride-treated mice supports this possi- 
bility (13, 14). The third possibility is molecular mimicry, 
in which the autoantibody response is induced in the host 
by infectious agents. The dassical example is the cross-reactivity 
of anti-Streptococcus A antibodies with cardiac myosin (39). 
There are increasing examples showing presence of shared 
antigenic peptide sequences between viral, bacterial, parasitic, 
and autoantigens (40). Sharing of peptide sequence homology 
between MBP and viral proteins (41), adenovirus-12 E1B pro- 
tein and gliadin A (42), gp210 protein reacting with autoan- 
tibodies from patients with primary biliary cirrhosis  (43), 
leucine zipper region of C-myc and V-myc with pT0 Ku au- 
toantigen (44), KAI.,1 antigen of river blindness pathogen 
Onchocera votvulus and 60-kD KO/SS-A autoantigen (45), 
regions of topoisomerase I with CMV (26) and mammalian 
type C virus P30~8 (46) are well documented. Sharing hex- 
apeptide sequence homologies between fibrillarin and EBV- 
encoded nucleoprotein and HSV type 1-encoded P40 sug- 
gests that molecular mimicry might play a significant  role 
in the induction of autoimmunity  and production of autoan- 
tibodies reacting with fibriliarin. 
The data presented here have twofold importance. First 
is the demonstration that autoantibodies specific for fibril- 
larin epitopes are produced in a number of connective tissue 
diseases in addition to SSc. Second is the demonstration of 
the presence of autoantibodies against immunodominant  epi- 
topes located at the NH2- and COOH-terminal regions of 
fibrillarin.  In addition, presence of homology between the 
NH2-terminal region of fibrillarin  and the nuclear  protein 
encoded by EBV on the one hand and capsid protein P40 
encoded by HSV and the COOH-terminal region of fibril- 
larin on the other hand suggests that common latent viruses 
might play a role in the induction of autoantibodies. Fur- 
thermore, correlation between the high incidence of antifibril- 
larin antibodies and the presence of EBV infection in SS pa- 
tients supports this. Studies are in progress to isolate mAbs 
against various fibriUarin epitopes and determine whether the 
antibodies specific for EBV-encoded nuclear protein or P40 
interact with fibrillarin peptides. Such experiments might shed 
light on the possible role of an antigen mimicry mechanism 
in the production of autoantibodies against  autoantigens. 
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